Cargando…

Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies

PURPOSE: To assess the frequency of patients reducing the use of artificial tears (ATs) among patients with dry eye disease (DED) following lifitegrast treatment. PATIENTS AND METHODS: Two independent analyses were performed using the data from the 1-year, randomized, multicenter, Phase 3 SONATA tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nichols, Kelly K, Donnenfeld, Eric D, Lau, Charis, Syntosi, Annie, Karpecki, Paul, Hovanesian, John A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965331/ https://www.ncbi.nlm.nih.gov/pubmed/35368241 http://dx.doi.org/10.2147/OPTH.S347496

Ejemplares similares

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease
por: Nichols, Kelly K, et al.
Publicado: (2018)

The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian, John, et al.
Publicado: (2020)

LIFITEGRAST 5% FOR DRY EYE DISEASE: COMBINED EFFICACY AND SAFETY FROM FIVE RANDOMIZED CONTROLLED TRIALS
por: Gonzalez, Agustin L, et al.
Publicado: (2019)

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra(®)) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
por: Hovanesian, John A, et al.
Publicado: (2021)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett, Ivonne V, et al.
Publicado: (2018)

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
por: Atallah, Richard Teofilo, et al.
Publicado: (2019)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose, Jay S, et al.
Publicado: (2019)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin, David, et al.
Publicado: (2021)

Lifitegrast: A novel drug for treatment of dry eye disease
por: Abidi, Afroz, et al.
Publicado: (2016)

Lifitegrast: a novel drug for patients with dry eye disease
por: Haber, Stacy L., et al.
Publicado: (2019)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba, Charles P, et al.
Publicado: (2016)

TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial
por: Gupta, Preeya K., et al.
Publicado: (2022)

Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
por: Torkildsen, Gail, et al.
Publicado: (2017)

Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials
por: Holland, Edward J., et al.
Publicado: (2021)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin, Morgan R, et al.
Publicado: (2017)

Dry eye: why artificial tears are not always the answer
por: Kim, Minji, et al.
Publicado: (2021)

Personalized Management of Dry Eye Disease: Beyond Artificial Tears
por: Matossian, Cynthia, et al.
Publicado: (2022)

Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis
por: Li, Jing-Xing, et al.
Publicado: (2022)

An evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye
por: Ousler, George, et al.
Publicado: (2015)

Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease
por: Labetoulle, Marc, et al.
Publicado: (2022)

Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape
por: Sheppard, John D., et al.
Publicado: (2023)

Effect of artificial tears on dynamic optical quality in patients with dry eye disease
por: Wei, Zhenyu, et al.
Publicado: (2022)

Tear proteomics in dry eye disease
por: Kannan, Ramaraj, et al.
Publicado: (2023)

A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare(®) System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease
por: Karpecki, Paul, et al.
Publicado: (2020)

Efficacy of an artificial tear emulsion in patients with dry eye associated with meibomian gland dysfunction
por: Sindt, Christine W, et al.
Publicado: (2013)

Evaluation of a Novel Artificial Tear in the Prevention and Treatment of Dry Eye in an Animal Model
por: She, Yujing, et al.
Publicado: (2015)

The efficacy of ocular surface assessment approaches in evaluating dry eye treatment with artificial tears
por: Szczesna-Iskander, Dorota H., et al.
Publicado: (2022)

Artificial intelligence to estimate the tear film breakup time and diagnose dry eye disease
por: Shimizu, Eisuke, et al.
Publicado: (2023)

Human Meibum and Tear Film Derived (O-Acyl)-Omega-Hydroxy Fatty Acids as Biomarkers of Tear Film Dynamics in Meibomian Gland Dysfunction and Dry Eye Disease
por: Khanal, Safal, et al.
Publicado: (2021)

Tear osmolarity and dry eye symptoms in diabetics
por: Fuerst, Nicole, et al.
Publicado: (2014)

Tear Luminex Analysis in Dry Eye Patients
por: Zhao, Hailan, et al.
Publicado: (2018)

The Effect of Artificial Tear Preparations with Three Different Ingredients on Contrast Sensitivity in Patients with Dry Eye Syndrome
por: Akkaya, Sezen
Publicado: (2018)

Tear Metabolomics in Dry Eye Disease: A Review
por: Yazdani, Mazyar, et al.
Publicado: (2019)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
por: Nichols, Kelly K, et al.
Publicado: (2018)

Cationic Emulsion-Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease
por: Daull, Philippe, et al.
Publicado: (2020)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez, Agustin L
Publicado: (2018)

Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease
por: White, Darrell E, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l0jsnqpldimeig2d785eu7dtkc